In addition, the panelists suggest that the administration of PCC or aPCC can be considered in a patient with life-threatening bleeding under FXa-inhibitor therapy in patients with atrial fibrillation if immediate haemostatic support is required, especially in situations where a specific reversal agent is not available. This evidence concerns the gene F10 and atrial fibrillation.